Full-Time

Director – AI Product / Program Delivery

Posted on 7/4/2026

Deadline 7/22/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$162.9k - $271.5k/yr

+ Bonus + Equity

No H1B Sponsorship

Phoenixville, PA, USA + 2 more

More locations: Groton, CT, USA | New York, NY, USA

In Person

Onsite 2.5 days per week required.

Bachelor's, Master's, PhD

Category
Business & Strategy (2)
,
Required Skills
Product Management
Risk Management

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • Bachelor’s degree with at least 8+ years of experience; OR a Master’s degree with more than 7+ years of experience; OR a Ph.D. with 5+ years of experience.
  • Experience with program or product management, delivery, or technical program cross-functional team management, including complex multi-stakeholder programs.
  • Experience building a business case and operating credibly with executive-level leadership.
  • Demonstrated ability to run technical delivery programs end-to-end — plans, milestones, dependencies, and risk.
  • Working fluency in AI / technical delivery — able to engage credibly with engineers on what is being built and why.
  • Experience coordinating vendors, contractors, and internal teams against scope, schedule, and budget.
  • Strong facilitation and stakeholder management, including with senior executives.
  • Excellent written and verbal communication; ability to make complexity legible.
Responsibilities
  • Vision & Strategy — Know the commercial strategy well enough to judge which problems are worth solving, set the direction for the initiative, and keep the work anchored to the outcomes the business actually cares about.
  • Business Case & Commercial Logic — Build the business case and carry it forward. Size the opportunity, define the bet, and make the call on where to invest and where to stop. You produce this — you don't commission it.
  • AI-First Leadership — Lead this as an AI-first effort, not a conventional program with AI added on top. Push the team to reach for AI where it changes the shape of the work, hold automation and intelligence as the default rather than the exception, and set the ways of working the rest of the portfolio can learn from.
  • Business Outcomes — Own the result and the work that gets there. Tie the initiative to commercial outcomes and drive measurable movement on them. When something isn't working, you're close enough to the work to catch it and change course
  • Hybrid Team & Delivery — Lead a team that is part people, part agents, and produce alongside it. Decide what humans do, what agents do, and how they work together — then build. You set the operating model and you stay in the work
  • Program & Delivery Management — Own the initiative plan and key milestones. Drive cadence and ceremonies, track progress against goals, manage dependencies and critical path, and keep delivery on schedule.
  • Reporting & Communication — Produce clear, honest status for the VP, business sponsor, and governance forums. Maintain the single source of truth on status, decisions, and risks.
Desired Qualifications
  • Experience in commercial pharma or regulated environments, and familiarity with promotional-review and compliance workflows.
  • Experience with agile delivery and modern program-management and collaboration tooling.
  • Exposure to AI- or data-driven products and delivery.
  • PMP, agile, or equivalent certification

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved HYMPAVZI expansions on August 6, 2026, broadening hemophilia access.
  • FDA approved PADCEV-Keytruda for muscle-invasive bladder cancer on July 10, 2026.
  • Pfizer raised Q2 2026 revenue guidance to $62.5 billion and added $2.5 billion savings.

What critics are saying

  • Eliquis exclusivity loss by 2028 threatens roughly $14 billion annual revenue.
  • Depo-Provera MDL trial starts December 2026 after 2,100-plus plaintiffs alleged missing warnings.
  • COVID vaccine patent wars with Moderna and Sanofi threaten royalties and management bandwidth.

What makes Pfizer unique

  • Pfizer's August 4, 2026 pipeline spans oncology, hemophilia, obesity, and vaccines.
  • Seagen assets, especially PADCEV, deepen Pfizer's oncology franchise after the 2023 acquisition.
  • Metsera gives Pfizer monthly obesity programs, a sharper angle than daily GLP-1 rivals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 4th, 2026
Pfizer Q2 earnings beat at 77¢/share, revenue guidance raised to $62.5B on non-COVID growth

Pfizer reported second-quarter revenue of $15.03 billion and raised its full-year revenue guidance to $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion. Adjusted earnings reached 77 cents per share, beating the 68-cent consensus estimate. Revenue growth was led by Eliquis, which rose 19% operationally, and Padcev, which climbed 23%. Paxlovid fell 95% amid lower COVID-19 infection rates, whilst Comirnaty declined 34%. Excluding COVID products, revenues grew 5% operationally. The company announced an additional $2.5 billion in cost savings expected from 2027 through 2029. CFO Dave Denton is departing on 15 August, with Cecile Guegan stepping in as interim CFO. Pfizer shares rose 1.8% to $25.50 in premarket trading.

Yahoo Finance
Aug 3rd, 2026
Pfizer returned $49B to shareholders but stock fell 21% over five years

Pfizer returned $49 billion to shareholders over five years through dividends and buybacks, equal to 34% of its current market value. Despite this substantial cash distribution, the stock delivered a -21% total return whilst the S&P 500 gained 81% over the same period. The pharmaceutical giant generated the payouts from a $63 billion business with a 25% operating margin. Of the total returned, $47 billion came from dividends and $2 billion from share repurchases. Management has affirmed its commitment to maintaining and growing dividends whilst reducing leverage. However, the company faces a "patent cliff" with $14-15 billion in annual revenue at risk from loss of exclusivity. Revenue growth stands at just 1.4% over the last twelve months, raising concerns that heavy payouts reflect fewer high-return reinvestment opportunities as core growth engines slow.

Associated Press
Jul 29th, 2026
Québec adopts Pfizer's Prevnar 20 vaccine for publicly funded pediatric pneumococcal immunisation

Québec has included Pfizer's PREVNAR 20 vaccine in its publicly funded paediatric pneumococcal immunisation programme as of May 2026. The province is the second in Canada to offer the 20-valent pneumococcal conjugate vaccine for routine infant immunisation, following British Columbia. PREVNAR 20 protects against 20 serotypes of Streptococcus pneumoniae, including seven additional strains associated with high fatality rates, antibiotic resistance, and meningitis. The vaccine is approved in Canada for preventing pneumonia and invasive pneumococcal disease in adults and for active immunisation of infants, children, and adolescents aged six weeks through 17 years. Québec's Comité sur l'immunisation recommends PREVNAR 20 as the vaccine of choice for routine immunisation of infants and children.

Yahoo Finance
Jul 27th, 2026
FDA grants Pfizer priority review for TALZENNA plus XTANDI in earlier prostate cancer

Pfizer announced the FDA has accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene-altered metastatic castration-sensitive prostate cancer. The application is supported by positive Phase 3 TALAPRO-3 results and existing approvals for later-stage disease. The Priority Review could broaden Pfizer's prostate cancer franchise into an earlier disease setting, potentially expanding the addressable patient population. However, the development does not change the core near-term risk around upcoming loss of exclusivity and pricing pressure. Pfizer's narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This implies a 4.6% yearly revenue decline, with earnings rising by about $1.7 billion from $7.5 billion today.

Yahoo Finance
Jul 22nd, 2026
Pfizer and Bluesight launch source-tagged RFID medications to streamline hospital pharmacy inventory management

Bluesight has partnered with Pfizer Global Hospital & Biosimilars to integrate RFID-enabled SmartDose medications with the KitCheck inventory management platform. The collaboration allows hospitals using KitCheck to receive medications pre-tagged and encoded at the point of manufacture, eliminating manual tagging work for pharmacy staff. Approximately one-third of US hospitals now use RFID technology to improve inventory management, enhance patient safety, and reduce medication waste. SmartDose medications are tagged during manufacturing using GS1 encoding standards, with each vial undergoing automated verification to ensure tags are readable and correctly encoded. The partnership aims to standardise RFID adoption across hospitals whilst maintaining efficiency and safety benefits. By shifting tagging upstream to manufacturing, the initiative reduces pharmacy workload and allows staff to focus more on patient care.

INACTIVE